Snss stock quote
Stock quote and company snapshot for SUNESIS PHARMACEUTICALS INC ( SNSS), including profile, stock chart, recent news and events, analyst opinions, SNSS shares outstanding history table and chart, presented by Many " beginner" or "novice" investors will look at one stock trading at a price of $10 per share This was a 1 for 6 reverse split, meaning for each 6 shares of SNSS owned Stock exchanges also tend to look at per-share price, setting a lower limit for listing Sunesis is a biopharmaceutical company focused on the development and commercialization of new oncology therapeutics for the potential treatment of solid Remember these companies are not worth the stock price. After allthese corona virus stocks, I am lucky to have made $2000 after risking many times that in
Researching Sunesis Pharmaceuticals (NASDAQ:SNSS) stock? View SNSS's stock price, price target, earnings, financials, forecast, insider trades, news, and
Sunesis is a biopharmaceutical company focused on the development and commercialization of new oncology therapeutics for the potential treatment of solid Remember these companies are not worth the stock price. After allthese corona virus stocks, I am lucky to have made $2000 after risking many times that in Information about which ETFs are holding the stock SNSS, Sunesis Pharmaceuticals Inc, from ETF Channel. Mar 8, 2019 Oppenheimer analyst Hartaj Singh lowered the price target on Sunesis Pharmaceuticals Inc. (NASDAQ: SNSS) to $6.00 (from $7.00) while Mar 11, 2020 SNSS. Sunesis. $0.96 /. -0.0177 (-1.81%). 05:29. 03/11/20. 03/11 Fortum price target lowered to EUR 14 from EUR 20 at UBS » 10:54 Shares of iQIYI are down 10.5% to $15.00 following the short report from Wolfpack Sep 3, 2019 If you like higher priced penny stocks, you could set the price limit to $5 or less. Sunesis Pharmaceuticals (SNSS Stock Report) was up big on
SNSS Sunesis Pharmaceuticals, Inc. Stock Quote
Mar 11, 2020 · Add SNSS Price Alert Hide Sticky Hide Intro Moderator: Search This Board: 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004 2003+
View today's stock price, news and analysis for Sunesis Pharmaceuticals Inc. (SNSS). Barron's also provides information on historical stock ratings, target prices, company earnings, market
This was a 1 for 6 reverse split, meaning for each 6 shares of SNSS owned Stock exchanges also tend to look at per-share price, setting a lower limit for listing Sunesis is a biopharmaceutical company focused on the development and commercialization of new oncology therapeutics for the potential treatment of solid Remember these companies are not worth the stock price. After allthese corona virus stocks, I am lucky to have made $2000 after risking many times that in Information about which ETFs are holding the stock SNSS, Sunesis Pharmaceuticals Inc, from ETF Channel. Mar 8, 2019 Oppenheimer analyst Hartaj Singh lowered the price target on Sunesis Pharmaceuticals Inc. (NASDAQ: SNSS) to $6.00 (from $7.00) while Mar 11, 2020 SNSS. Sunesis. $0.96 /. -0.0177 (-1.81%). 05:29. 03/11/20. 03/11 Fortum price target lowered to EUR 14 from EUR 20 at UBS » 10:54 Shares of iQIYI are down 10.5% to $15.00 following the short report from Wolfpack Sep 3, 2019 If you like higher priced penny stocks, you could set the price limit to $5 or less. Sunesis Pharmaceuticals (SNSS Stock Report) was up big on
Sunesis Pharmaceuticals, Inc. is a biopharmaceutical company. The Company focuses on the development and commercialization of its pipeline of oncology therapeutics for the treatment of solid and hematologic cancers.
Remember these companies are not worth the stock price. After allthese corona virus stocks, I am lucky to have made $2000 after risking many times that in Information about which ETFs are holding the stock SNSS, Sunesis Pharmaceuticals Inc, from ETF Channel.
Here are some recent quotes from research analysts about Sunesis Pharmaceuticals stock: 1. According to Zacks Investment Research, "Sunesis Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule therapeutics for oncology and other serious diseases.